Lesko LJ - Search Results

1

The Creating an Optimal Warfarin Nomogram (CROWN) Study.

Perlstein TS, Goldhaber SZ, Nelson K, Joshi V, Morgan TV, Lesko LJ, Lee JY, Gobburu J, Schoenfeld D, Kucherlapati R, Freeman MW, Creager MA. Perlstein TS, et al. Among authors: lesko lj. Thromb Haemost. 2012 Jan;107(1):59-68. doi: 10.1160/TH11-08-0568. Epub 2011 Nov 24. Thromb Haemost. 2012. PMID: 22116191 Free PMC article. Clinical Trial.

2

Quantitative disease, drug, and trial models.

Gobburu JV, Lesko LJ. Gobburu JV, et al. Among authors: lesko lj. Annu Rev Pharmacol Toxicol. 2009;49:291-301. doi: 10.1146/annurev.pharmtox.011008.145613. Annu Rev Pharmacol Toxicol. 2009. PMID: 18851702 Review.

3

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.

Gage BF, Lesko LJ. Gage BF, et al. Among authors: lesko lj. J Thromb Thrombolysis. 2008 Feb;25(1):45-51. doi: 10.1007/s11239-007-0104-y. Epub 2007 Oct 1. J Thromb Thrombolysis. 2008. PMID: 17906972 Review.

4

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.

Kim MJ, Huang SM, Meyer UA, Rahman A, Lesko LJ. Kim MJ, et al. Among authors: lesko lj. J Clin Pharmacol. 2009 Feb;49(2):138-46. doi: 10.1177/0091270008328098. J Clin Pharmacol. 2009. PMID: 19179293 Review.

5

Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.

Gobburu JV, Tammara V, Lesko L, Jhee SS, Sramek JJ, Cutler NR, Yuan R. Gobburu JV, et al. J Clin Pharmacol. 2001 Oct;41(10):1082-90. doi: 10.1177/00912700122012689. J Clin Pharmacol. 2001. PMID: 11583476 Clinical Trial.

6

Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.

Wang Y, Bhattaram AV, Jadhav PR, Lesko LJ, Madabushi R, Powell JR, Qiu W, Sun H, Yim DS, Zheng JJ, Gobburu JV. Wang Y, et al. Among authors: lesko lj. J Clin Pharmacol. 2008 Feb;48(2):146-56. doi: 10.1177/0091270007311111. J Clin Pharmacol. 2008. PMID: 18199891

7

Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.

Lee JY, Garnett CE, Gobburu JV, Bhattaram VA, Brar S, Earp JC, Jadhav PR, Krudys K, Lesko LJ, Li F, Liu J, Madabushi R, Marathe A, Mehrotra N, Tornoe C, Wang Y, Zhu H. Lee JY, et al. Among authors: lesko lj. Clin Pharmacokinet. 2011 Oct;50(10):627-35. doi: 10.2165/11593210-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21895036

8

Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.

Shaw K, Amstutz U, Kim RB, Lesko LJ, Turgeon J, Michaud V, Hwang S, Ito S, Ross C, Carleton BC; CPNDS Clinical Recommendation Group. Shaw K, et al. Among authors: lesko lj. Ther Drug Monit. 2015 Aug;37(4):428-36. doi: 10.1097/FTD.0000000000000192. Ther Drug Monit. 2015. PMID: 26186657 Free article. Review.

9

Essential pharmacokinetic information for drug dosage decisions: a concise visual presentation in the drug label.

Menon-Andersen D, Yu B, Madabushi R, Bhattaram V, Hao W, Uppoor RS, Mehta M, Lesko L, Temple R, Stockbridge N, Laughren T, Gobburu JV. Menon-Andersen D, et al. Clin Pharmacol Ther. 2011 Sep;90(3):471-4. doi: 10.1038/clpt.2011.149. Epub 2011 Jul 27. Clin Pharmacol Ther. 2011. PMID: 21796114 No abstract available.

10

The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics.

Lesko LJ. Lesko LJ. Clin Pharmacol Ther. 2008 Sep;84(3):301-3. doi: 10.1038/clpt.2008.133. Clin Pharmacol Ther. 2008. PMID: 18714317 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

218 results

Search Page

Filters